Under the deal, the companies will develop novel skin care products. Initially, the partnership will develop private labeled skin protectant products, including next generation antimicrobial barrier film.

Skin protectants will help to prevent and treat incontinence related sermatitis (IAD), a crucial factor in pressure ulcer development.

The new product line will expand Mölnlycke’s skin care assortment and full portfolio, including wound dressings with Safetac technology and patient positioning solutions.

Both firms have also signed a joint development agreement on future products, providing Mölnlycke access to Rochal’s technical expertise.

Rochal will develop commercially viable innovations in conjunction with Mölnlycke, who in turn will commercialize further new patented platform technologies

Mölnlycke Health Care CEO Richard Twomey said: “Skin protectants are strategically important to our Prevention solution offer and the partnership with Rochal enables us to provide our customers with a complete solution within the pressure ulcer prevention area.”

Rochal Industries CEO Ann Beal Salamone said: “The emergent products Rochal has developed for protecting skin including the antimicrobial barrier film are patent protected technological innovations that we are excited to have Mölnlycke bring to the market.”

Mölnlycke Health Care produces products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery, while Rochal develops technology solutions in polymer, antimicrobial, biological systems and related fields.